Expertise · Anabolics & SARMs
The practice covers nandrolone, oxandrolone, stanozolol, ostarine, ligandrol and other SARMs/PEDs. These agents may be prescribed, compounded or supplied outside any approved indication. An endocrinologist reviews the pharmacology and the paper trail. Matters may involve sports law, anti-doping or malpractice litigation.
Anabolic steroid and SARM matters differ from ordinary prescribing cases. The therapy usually had no legitimate indication to begin with. The dispute is rarely whether guidelines were followed. None endorse these protocols. The issue is what a physician who prescribed anyway owed the patient. That includes baseline screening, honest disclosure of endocrine and cardiovascular costs, and monitoring capable of catching the harm these agents predictably cause.
As an endocrinologist, I treat the gonadal axis these drugs suppress every day. I can explain to a court how nandrolone or ostarine acts on it. I can explain what injury was foreseeable at the dose in the record. I can also identify where supervised therapy ended and performance supply began. That is the question on which most of these cases turn.
Case Patterns
Nandrolone, oxandrolone and stanozolol prescribed outside any approved indication — often layered on top of testosterone in "performance" or "body recomposition" protocols. Hepatic injury, dyslipidemia, cardiomyopathy and thrombotic events each demand a baseline and a monitoring schedule the chart rarely contains.
Ostarine, ligandrol, RAD-140 and similar agents with no approved use in humans, sold as supplements or "research chemicals" and increasingly recommended in clinic. Drug-induced liver injury and axis suppression dominate these files — along with the question of what the seller or prescriber represented about safety.
Suppression of the hypothalamic-pituitary-gonadal axis is a predictable consequence of every agent in this class, yet consent discussions rarely mention it. Young men left hypogonadal or infertile after a supervised protocol raise a clean standard-of-care question: was the known endocrine cost ever disclosed or managed?
The decisive question in many files is where medicine ended and supply began — a clinic dispensing escalating doses without visits, labs ordered but never reviewed, or a prescriber signing for a protocol a coach designed. I map the record to show exactly where clinical judgment stopped being exercised.
Cardiomyopathy, left ventricular hypertrophy and sudden cardiac death in long-term users — matters where causation is contested and the toxicology, autopsy findings and use history have to be read together. I address what the literature supports, and just as carefully, what it does not.
What the Record Shows
Related expertise
For expert review, opinion or testimony in an anabolic steroid, SARM or performance-enhancing drug matter.
Enquire about a matter